Vascular dementia, unspecified severity, with psychotic disturbance
Methodology & AI Transparency ⓘ
Vascular dementia, unspecified severity, with psychotic disturbance Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Cataloged under federal diagnostic code F01.52 in Memory & Cognition, Vascular dementia, unspecified severity, with psychotic disturbance requires volumetric brain MRI [Vascular dementia, unspecified severity, with psychotic disturbance F01.52] so specialists can calibrate treatment intensity against TSH & Fasting in Vascular dementia, unspecified severity, with psychotic disturbance (F01.52: ApoB / HbA1c) benchmarks.
- 2 Real-world patient consensus: Clinical coding for Vascular dementia, unspecified severity, with psychotic disturbance uses ICD-10 F01.52 across Memory & Cognition specialty care.
- 3 Typical cash cost range: Clinicians assessing Vascular dementia, unspecified severity, with psychotic disturbance focus on neuroinflammatory microglial activation [Vascular dementia, unspecified severity, with psychotic disturbance F01.52] and targeted history.
- 4 Top reported side effects / signs: Objective lab/clinical target for Vascular dementia, unspecified severity, with psychotic disturbance: TSH & Fasting in Vascular dementia, unspecified severity, with psychotic disturbance (F01.52: ApoB / HbA1c) (Optimal cardiometabolic neuroprotection (F01.52)) and MoCA Cognitive Screening in Vascular dementia, unspecified severity, with psychotic disturbance (F01.52: Score).
Ask our AI Specialists anything about Vascular dementia, unspecified severity, with psychotic disturbance
What Is Vascular dementia, unspecified severity, with psychotic disturbance?
Cataloged under federal diagnostic code F01.52 in Memory & Cognition, Vascular dementia, unspecified severity, with psychotic disturbance requires volumetric brain MRI [Vascular dementia, unspecified severity, with psychotic disturbance F01.52] so specialists can calibrate treatment intensity against TSH & Fasting in Vascular dementia, unspecified severity, with psychotic disturbance (F01.52: ApoB / HbA1c) benchmarks.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Vascular dementia, unspecified severity, with psychotic disturbance (ICD-10 F01.52) is driven by neuroinflammatory microglial activation [Vascular dementia, unspecified severity, with psychotic disturbance F01.52]; specialists in Alzheimer, Dementia & Memory Health monitor MoCA Cognitive Screening in Vascular dementia, unspecified severity, with psychotic disturbance (F01.52: Score) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Vascular dementia, unspecified severity, with psychotic disturbance (F01.52): slowed processing speed in Vascular dementia, unspecified severity, with psychotic disturbance (F01.52: compared with prior)
- • Secondary Vascular dementia, unspecified severity, with psychotic disturbance clinical sign: short-term recall difficulty in Vascular dementia, unspecified severity, with psychotic disturbance (F01.52: for recent conversations,)
- • Symptom flares in Vascular dementia, unspecified severity, with psychotic disturbance correlating with TSH & Fasting in Vascular dementia, unspecified severity, with psychotic disturbance (F01.52: ApoB / HbA1c) deviation outside Optimal cardiometabolic neuroprotection (F01.52)
- • Functional memory & cognition impact requiring volumetric brain MRI [Vascular dementia, unspecified severity, with psychotic disturbance F01.52] evaluation (F01.52)
Vascular dementia, unspecified severity, with psychotic disturbance Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | F01.52 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Alzheimer, Dementia & Memory Health | NLM Clinical Tables |
| Diagnostic / Lab Marker: TSH & Fasting in Vascular dementia, unspecified severity, with psychotic disturbance (F01.52: ApoB / HbA1c) | Optimal cardiometabolic neuroprotection (F01.52) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: MoCA Cognitive Screening in Vascular dementia, unspecified severity, with psychotic disturbance (F01.52: Score) | >= 26 / 30 (F01.52) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Homocysteine & Vitamin in Vascular dementia, unspecified severity, with psychotic disturbance (F01.52: B12) | Homocysteine < 9 umol/L; B12 > 500 pg/mL (F01.52) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Vascular dementia, unspecified severity, with psychotic disturbance
Treatment selection for Vascular dementia, unspecified severity, with psychotic disturbance depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Vascular dementia, unspecified severity, with psychotic disturbance)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Achieved blood pressure and heart and blood vessel outcomes in high-risk: What a 8,407-Participant Study Found Mean achieved SBP less than 120 mm Hg during treatment was associated with increased risk of heart and blood vessel outcomes except for heart attack and stroke. Lancet (London, England) • 2017-06-03 • Meta-Analysis | N = 8,407 | 99/100 | PMID 28390695 ↗ |
| New Insights on Effect of Glucagon-like Peptide-1 Receptor Agonists on All-cause Mortality and: What a 21,135-Participant Study Found GLP1RA therapy when compared to placebo reduced all-cause mortality in high heart and blood vessel risk patients with type 2 diabetes. Current diabetes reviews • 2018-01-15 • Meta-Analysis | N = 21,135 | 99/100 | PMID 28413990 ↗ |
| New Insights on Heart and blood vessel outcomes of liraglutide in patients with type 2: What a 14,608-Participant Study Found Our results suggest that liraglutide treatment decreases the risk of MACE, AMI, all-cause death and heart and blood vessel death among patients with type 2 diabetes. Medicine • 2019-11-15 • Meta-Analysis | N = 14,608 | 99/100 | PMID 31725627 ↗ |
| New Insights on Effect of metformin on microvascular outcomes in patients with type 2: What a 18,181-Participant Study Found There is no evidence of clinically significant beneficial effect of metformin therapy as compared to other glucose-lowering medications or placebo on the examined microvascular complications. Diabetes research and clinical practice • 2022-04-15 • Meta-Analysis | N = 18,181 | 99/100 | PMID 35247521 ↗ |
| New Insights on Association between testosterone replacement therapy and heart and blood vessel: What a 11,502-Participant Study Found Our analysis indicates that for patients with hypogonadism, testosterone replacement therapy does not increase the CVD risk and all-cause mortality. Progress in cardiovascular diseases • 2024-01-15 • Meta-Analysis | N = 11,502 | 99/100 | PMID 38589271 ↗ |
Vascular dementia, unspecified severity, with psychotic disturbance Patient Community & “People Like Me” Threads
Filter Vascular dementia, unspecified severity, with psychotic disturbance community threads and patient logs by age, biological sex, dosage, and treatment duration.